Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology

Journal of the American Academy of Dermatology

Volumn 47, Issue 2, 2002, Pages 169-190

  Berlin, Alexander L ^a   Paller, Amy S ^b   Chan, Lawrence S ^a,c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME XQ; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EYE DISEASE; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENODERMATOSIS; HAIR DISEASE; HISTOPATHOLOGY; HUMAN; INCONTINENTIA PIGMENTI; KNOCKOUT MOUSE; MOUSE; NAIL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SOCIAL SUPPORT; TOOTH DISEASE; X CHROMOSOME DOMINANT DISORDER;

EID: 0036696739     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.125949     Document Type: Article

References (146)

1. Garrod AE. Peculiar pigmentation of the skin of an infant. Trans Clin Soc Lond 1906;39:216.
2. Bloch B. Eigentumliche bischer nicht beschriebene pigmentaffektion (incontinentia pigmenti), Schweiz Med Wochenschr 1926;7:404-5.
3. Sulzberger MB, Uber eine bischer nicht beschriebene congenitale pigmentanomalie (incontinentia pigmenti). Arch Dermatol Syph (Berl) 1928;154:19-32.
4. Gurevitch AW, Farrell W, Horlick S, Hirose F, Reisner RM. Incontinentia pigmenti - a systemic genodermatosis with striking cutaneous findings. Clin Pediatr 1973;12;396-401.
5. Carney RG Jr. Incontinentia pigmenti: a world statistical analysis. Arch Dermatol 1976;112:535-42.
6. Scheuerle AE. Male cases of incontinentia pigmenti: case report and review. Am J Med Genet 1998;77:201-18.
7. Wettke-Schäfer R, Kanter G. X-linked dominant inherited diseases with lethality in hemizygous males. Hum Genet 1983;64: 1-23.
8. Gordon H, Gordon W. Incontinentia pigmenti: clinical and genetical studies of two familial cases. Dermatologica 1970;140: 150-68.
9. Curth HO, Warburton D. The genetics of incontinentia pigmenti. Arch Dermatol 1965;92:229-35.
10. Devriendt K, Matthijs G, Fryns JP, Ballegeer V. Second trimester miscarriage of a male fetus with incontinentia pigmenti. Am J Med Genet 1998;80:298-9.
11. Ormerod AD, White MI, McKay E, Johnston AW. Incontinentia pigmenti in a boy with Klinefelter's syndrome. J Med Genet 1987;24:439-41.
12. Garcia-Dorado J, de Unamuno P, Fernandez-Lopez E, Salazar Veloz J, Armijo M. Incontinentia pigmenti: XXY male with a family history. Clin Genet 1990;38:128-38.
13. Kenwrick S. Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am J Hum Genet 2001;69: 1210-7.
14. Wiklund DA, Weston WL. Incontinentia pigmenti: a four-generation study. Arch Dermatol 1980;116:701-3.
15. Happle R. Lyonization and the lines of Blaschko. Hum Genet 1985;70:200-6.
16. Jackson R. The lines of Blaschko: a review and reconsideration. Br J Dermatol 1976;95:349-60.
17. Landy SJ, Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet 1993;30:53-9.
18. O'Brien JE, Feingold M. Incontinentia pigmenti: a longitudinal study. Am J Dis Child 1985;139:711-2.
19. Pfau A, Landthaler M. Recurrent inflammation in incontinentia pigmenti of a seven-year-old child. Dermatology 1995;191:161-3.
20. Bessens PJMJ, Jagtman BA, van de Staak WJBM, Hulsmans RFHJ, Croughs KJM. Progressive, persistent, hyperkeratotic lesions in incontinentia pigmenti. Arch Dermatol 1988;124:29-30.
21. Di Landro A, Marchesi L, Reseghetti A, Cainelli T. Warty linear streaks of the palm and sole: possible late manifestations of incontinentia pigmenti. Br J Dermatol 2000;143:1102-3.
22. Felt SE, Jacobs DE. Incontinentia pigmenti. J Kans Med Soc 1973;74:43-5.
23. Harre J, Millikan LE. Linear and whorled pigmentation. Int J Dermatol 1994;8:529-37.
24. Moss C, Ince P. Anhidrotic and achromians lesions in incontinentia pigmenti. Br J Dermatol 1987;116:839-50.
25. Abimelec P, Rybojad M, Cambiaghi S, Moraillon I, Cavelier-Balloy B, Marx C, et al. Late, painful, subungual hyperkeratosis in incontinentia pigmenti. Pediatr Dermatol 1995;12:340-2.
26. Mascaro JM, Palou J, Vives P. Painful subungual keratotic tumors in incontinentia pigmenti. J Am Acad Dermatol 1985;13: 913-8.
27. Adeniran A, Townsend PLG, Peachey RDG. Incontinentia pigmenti (Bloch-Sulzberger syndrome) manifesting as painful periungual and subungual tumours. J Hand Surg [Br] 1993;18: 667-9.
28. Simmons DA, Kegel MF, Scher RK, Hines YC. Subungual tumors in incontinentia pigmenti. Arch Dermatol 1986;122:1431-4.
29. Russel DL, Finn SB. Incontinentia pigmenti (Bloch-Sulzberger Syndrome): a case report with emphasis on dental manifestations. J Dent Child 1967;34:494-500.
30. Niccoli-Filho WD, da Rocha JC, Di Nicolo R, Seraidarian PI. Incontinentia pigmenti (Bloch-Sulzberger syndrome): a case report. J Clin Pediatr Dent 1993;17:251-3.
31. Rouse JS. Incontinentia pigmenti: overcoming cosmetic challenges. Compend Contin Educ Dent 1999;20:1034-6,1038,1040-1.
32. François J. Incontinentia pigmenti (Bloch-Sulzberger syndrome) and retinal changes. Br J Ophthalmol 1984;68:19-25.
33. McCrary JA III, Smith JL. Conjunctival and retinal incontinentia pigmenti. Arch Ophthalmol 1968;79:417-22.
34. Goldberg MF. The blinding mechanisms of incontinentia pigmenti. Ophthalmic Genet 1994;15:69-76.
35. Rosenfeld SI, Smith ME. Ocular findings in incontinentia pigmenti. Ophthalmology 1985;92:543-6.
36. Goldberg MF, Custis PH. Retinal and other manifestations of incontinentia pigmenti (Bloch-Sulzberger syndrome). Ophthalmology 1993;100:1645-54.
37. Chao AN, Lai CC, Kao LY, Hsu JF, Yang KJ, Chen TL. Incontinentia pigmenti: a florid case with a fulminant clinical course in a newborn. Retina 2000;20:558-60.
38. Rahi J, Hungerford J. Early diagnosis of the retinopathy of incontinentia pigmenti: successful treatment by cryotherapy. Br J Ophthalmol 1990;74:377-9.
39. Francis JS, Sybert VP. Incontinentia pigmenti. Semin Cutan Med Surg 1997;16:54-60.
40. Holmström G, Thorén K. Ocular manifestations of incontinentia pigmenti. Acta Ophthalmol Scand 2000;78:348-53.
41. Larsen R, Ashwal S, Peckham N. Incontinentia pigmenti: association with anterior horn cell degeneration. Neurology 1987; 37:446-50.
42. Brunquell PJ. Recurrent encephalomyelitis associated with incontinentia pigmenti. Pediatr Neurol 1987;3:174-7.
43. Yell JA, Walshe M, Desai SN. Incontinentia pigmenti associated with bilateral cleft lip and palate. Clin Exp Dermatol 1991;16: 49-50.
44. Diamantopoulos N, Bergman I, Kaplan S. Actinomycosis meningitis in a girl with incontinentia pigmenti. Clin Pediatr 1985; 24:651-4.
45. Miteva L, Nikolova A. Incontinentia pigmenti: a case associated with cardiovascular abnormalities. Pediatr Dermatol 2001;18: 54-6.
46. Roberts WM, Jenkins JJ, Moorhead EL, Douglass EC. Incontinentia pigmenti, a chromosomal instability syndrome, is associated with childhood malignancy. Cancer 1988;62:2370-2.
47. Kajii T, Tsukahara M, Fukushima Y, Hata A, Matsuo K, Kuroki Y. Translocation (X;13)(p11.21;q12.3) in a girl with incontinentia pigmenti and bilateral retinoblastoma. Ann Genet 1985;4:219-23.
48. Blake J, Mullaney J. Retinoblastoma in Bloch-Sulzberger syndrome. Ophthalmologica 1976;172:457-65.
49. Kadotani T, Watanabe J, Shimoda H. A chromosome study of a patient with Wilms' tumor. Proc Jpn Acad (B) 1984;60:191-4.
50. Rivera R, Vangir A, Strong L. Incontinentia pigmenti (Bloch-Sulzberger syndrome) associated with acute granulocytic leukemia. South Med J 1975;68:1391-4.
51. Shashikumar VL, Somers LA, Pilling GP, Creeson SL. Wilms' tumor in the horseshoe kidney. J Pediatr Surg 1974;9:185-9.
52. Machado-Pinto J, McCalmont TH, Golitz LE. Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders. Semin Cutan Med Surg 1996;15:308-16.
53. Worret WI, Nordquist RE, Burgdorf WHC. Abnormal cutaneous nerves in incontinentia pigmenti. Ultrastruct Pathol 1988;12: 449-54.
54. Zillikens D, Mehringer A, Lechner W, Burg G. Hypo- and hyperpigmented areas in incontinentia pigmenti: light and electron microscopic studies. Am J Dermatopathol 1991;13:57-62.
55. Rott HD. Partial sweat gland aplasia in incontinentia pigmenti Bloch-Sulzberger: implications for nosologic classification. Clin Genet 1984;26:36-8.
56. Mensheha-Manhart O, Rodrigues MM, Shields JA, Shannon GM, Mirabelli RP. Retinal pigment epithelium in incontinentia pigmenti. Am J Ophthalmol 1975;79:571-7.
57. Schaumburg-Lever G, Lever WF. Electron microscopy of incontinentia pigmenti. J Invest Dermatol 1973;61:151-8.
58. Dahl MV, Matula G, Leonards R, Tuffanelli DL. Incontinentia pigmenti and defective neutrophil chemotaxis. Arch Dermatol 1975;111:1603-5.
59. Menni S, Piccinno R, Biolchini A, Plebani A. Immunologic investigations in eight patients with incontinentia pigmenti. Pediatr Dermatol 1990;7:275-7.
60. Jessen RT, Van Epps DE, Goodwin JS, Bowerman J. Incontinentia pigmenti. Evidence for both neutrophil and lymphocyte dysfunction. Arch Dermatol 1978;114:1182-6.
61. Avrahami E, Harel S, Jurgenson U, Cohn DF. Computed tomographic demonstration of brain changes in incontinentia pigmenti. Am J Dis Child 1985;139:372-4.
62. Chatkupt S, Gozo AO, Wolansky LJ, Sun S. Characteristic MR findings in a neonate with incontinentia pigmenti. AJR Am J Roentgenol 1993;160:372-4.
63. Lee AG, Goldberg MF, Gillard JH, Barker PB, Bryan RN. Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging. Arch Pediatr Adolesc Med 1995;149:573-80.
64. Pascual-Castroviejo I, Roche MC, Martinez Fernandez V, Perez-Romero M, Escudero RM, Garcia-Penas JJ, et al. Incontinentia pigmenti: MR demonstration of brain changes. AJNR Am J Neuroradiol 1994;15:1521-7.
65. Kasai T, Kato Z, Matsui E, Sakai A, Nishida T, Kondo N, et al. Cerebral infarction in incontinentia pigmenti: the first report of a case evaluated by single photon emission computed tomography. Acta Paediatr 1997;86:665-7.
66. Aydingozm U, Midia M. Central nervous system involvement in incontinentia pigmenti: cranial MRI of two siblings. Neuroradiology 1998;40:364-6.
67. Mirowski GW, Caldemeyer KS. Incontinentia pigmenti. J Am Acad Dermatol 2000;43:517-8.
68. Vicente-Villa A, Lamas JV, Pascual AM, Cuesta DL, Marfa MP, Gonzalez-Ensenat MA. Incontinentia pigmenti: a report of ten cases. Eur J Pediatr 2001;160:64-5.
69. Sahn EE. Vesiculopustular diseases of neonates and infants. Curr Opin Pediatr 1994;6:442-6.
70. Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med 2000;18:288-99.
71. Roholt NS, Lapiere JC, Wang JI, Bernstein U, Woodley DT, Eramo LR. Localized linear bullous eruption of systemic lupus erythematosus in a child. Pediatr Dermatol 1995;12:138-44.
72. Marinkovich MP. Update on inherited bullous dermatoses. Dermatol Clin 1999;17:473-85,vii.
73. Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol 2001;42:15-21.
74. Ciarallo L, Paller AS. Two cases of incontinentia pigmenti simulating child abuse. Pediatrics 1997;100:E6.
75. Rogers M, McCrossin I, Commens C. Epidermal nevi and the epidermal nevus syndrome. J Am Acad Dermatol 1989;20:476-88.
76. Kennedy D, Rogers M. Lichen striatus. Pediatr Dermatol 1996; 13:95-9.
77. Kalter DC, Griffiths WA, Atherton DJ. Linear and whorled nevoid hypermelanosis. J Am Acad Dermatol 1988;19:1037-44.
78. Heimer WL II, Brauner G, James WD. Dermatopathia pigmentosa reticularis: a report of a family demonstrating autosomal dominant inheritance. J Am Acad Dermatol 1992;26:298-301.
79. Itin PH, Lautenschlager S, Meyer R, Mevorah B, Rufli T. Natural history of the Naegeli-Franceschetti-Jadassohn syndrome and further delineation of its clinical manifestations. J Am Acad Dermatol 1993;28:942-50.
80. Happle R. X-linked dominant chondrodysplasia punctata. Hum Genet 1979;53:65-73.
81. Takematsu H, Sato S, Igarashi M, Seiji M. Incontinentia pigmenti achromians (Ito). Arch Dermatol 1983;119:391-5.
82. Sybert VP. Hypomelanosis of Ito: a description, not a diagnosis. J Invest Dermatol 1994;103(Suppl):141S-143S.
83. Goltz RW, Henderson RR, Hitch JM, Ott JE. Focal dermal hypoplasia syndrome. Arch Dermatol 1970;101:1-11.
84. Hardman CM, Garioch JJ, Eady RA, Fry L. Focal dermal hypoplasia: report of a case with cutaneous and skeletal manifestations. Clin Exp Dermatol 1998;23:281-5.
85. Nagase T, Takanashi M, Takada H, Ohmori K. Extensive vesiculobullous eruption following limited ruby laser treatment for incontinentia pigmenti: a case report. Australas J Dermatol 1997;38:155-7.
86. Patel MR, Desai S. Subungual keratoacanthoma in the hand. J Hand Surg [Am] 1989;14:139-42.
87. Malvehy J, Palou J, Mascaro JM. Painful subungual tumour in incontinentia pigmenti. Response to treatment with etretinate. Br J Dermatol 1998;138:554-5.
88. 2 laser in the treatment of periungual fibromas associated with tuberous sclerosis. Dermatol Surg 2002;28:434-6.
89. Sahn EE, Davidson LS. Incontinentia pigmenti: three cases with unusual features. J Am Acad Dermatol 1994;31:852-7.
90. Watzke RC, Stevens TS, Carney RG Jr. Retinal vascular changes in incontinentia pigmenti. Arch Ophthalmol 1976;94:743-6.
91. Nix RR, Apple DJ. Proliferative retinopathy associated with incontinentia pigmenti. Retina 1981;1:156-61.
92. Catalano RA, Lopatynsky M, Tasman WS. Treatment of proliferative retinopathy associated with incontinentia pigmenti. Am J Ophthalmol 1990;110:701-2.
93. Wald KJ, Mehta MC, Katsumi O, Sabates NR, Hirose T. Retinal detachments in incontinentia pigmenti. Arch Ophthalmol 1993;111:614-7.
94. Fekrat S, Humayun MS, Goldberg MF. Spontaneous retinal reattachment in incontinentia pigmenti. Retina 1998;18:75-7.
95. Reed WB, Carter C, Cohen TM. Incontinentia pigmenti. Dermatologica 1967;134:243-50.
96. Bernstein R, Dawson B, Kohl R, Jenkins T.X;15 translocation in a retarded girl: X inactivation pattern and attempt to locate the hexosaminidase A and other loci. J Med Genet 1979;16:254-62.
97. Gilgenkrantz S, Tridon P, Pinel-Briquel N, Beurey J, Weber M. Translocation (X;9) (p11;q34) in a girl with incontinentia pigmenti (IP): implications for the regional assignment of the IP locus to Xp11? Ann Genet 1985;28:90-2.
98. Hodgson SV, Neville B, Jones RW, Fear C, Bobrow M. Two cases of X/autosome translocation in females with incontinentia pigmenti. Hum Genet 1985;71:231-4.
99. de Grouchy J, Turleau C, Doussau de Bazignan M, Maroteaux P, Thibaud D. Incontinentia pigmenti (IP) and r (X). Tentative mapping of the IP locus to the X juxtacentromeric region. Ann Genet 1985;28:86-9.
100. Cannizzaro LA, Hecht F. Gene for incontinentia pigmenti maps to band Xp11 with an (X;10)(p11;q22) translocation. Clin Genet 1987;32:66-9.
101. Bitoun P, Philippe C, Cherif M, Mulcahy MT, Gilgenkrantz S. Incontinentia pigmenti (type 1) and X; 5 translocation. Ann Genet 1992;35:51-4.
102. Happle R. Tentative assignment of hypomelanosis of Ito to 9q33-qter. Hum Genet 1987;75:98-9.
103. Sybert VP. Incontinentia pigmenti nomenclature. Am J Hum Genet 1994;55:209-11.
104. Sybert VP. A case revisited: recent presentation of incontinentia pigmenti in association with a previously reported X; autosome translocation. Am J Med Genet 1998;75:334.
105. Harris A, Lankester S, Haan E, Beres J, Hulten M, Szollar J, et al. The gene for incontinentia pigmenti: failure of linkage studies using DNA probes to confirm cytogenetic localization. Clin Genet 1988;34:1-6.
106. Sefiani A, Sinnett D, Abel L, Szpiro-Tapia S, Heuertz S, Craig I, et al. Linkage studies do not confirm the cytogenetic location of incontinentia pigmenti on Xp11. Hum Genet 1988;80:282-6.
107. Sefiani A, Abel L, Heuertz S, Sinnett D, Lavergne L, Labuda D, et al. The gene for incontinentia pigmenti is assigned to Xq28. Genomics 1989;4:427-9.
108. Smahi A, Hyden-Granskog C, Peterlin B, Vabres P, Heuertz S, Fulchignoni-Lataud MC, et al. The gene for the familial form of incontinentia pigmenti (IP2) maps to the distal part of Xq28. Hum Mol Genet 1994;3:273-8.
109. Jin DY, Jeang KT. Isolation of full-length CDNA and chromosomal localization of human NF-kappaB modulator NEMO to Xq28. J Biomed Sci 1999;6:115-20.
110. Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405:466-72.
111. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
112. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
113. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274: 782-4.
114. Liu ZG, Hsu H,Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996;87: 565-76.
115. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol 1998;8: 107-11.
116. Courtois G, Smahi A, Israel A. NEMO/IKKgamma: linking NF-kappaB to human disease. Trends Mol Med 2001;7:427-30.
117. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35.
118. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998;395:297-300.
119. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998;93:1231-40.
120. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 2000;14:854-62.
121. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T, et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000; 5:969-79.
122. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, Rajewsky K, et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell 2000;5:981-92.
123. Parrish JE, Scheuerle AE, Lewis RA, Levy ML, Nelson DL. Selection against mutant alleles in blood leukocytes is a consistent feature in incontinentia pigmenti type 2. Hum Mol Genet 1996; 5:1777-83.
124. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
125. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. Hsp70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42.
126. Musso M, Ghiorzo P, Fiorentini P, Giuffrida R, Ciotti P, Garre C, et al. An upstream positive regulatory element in human GM-CSF promoter is recognized by NF-kappa B/Rel family members. Biochem Biophys Res Commun 1996;223:64-72.
127. Temkin V, Levi-Schaffer F. Mechanism of tumour necrosis factor alpha mediated eosinophil survival. Cytokine 2001;15:20-6.
128. Mori A, Kaminuma O, Mikami T, Inoue S, Okumura Y, Akiyama K, et al. Transcriptional control of the IL-5 gene by human helper T cells: IL-5 synthesis is regulated independently from IL-2 or IL-4 synthesis. J Allergy Clin Immunol 1999;103:S429-36.
129. Tsuda S, Higuchi M, Ichiki M, Sasai Y. Demonstration of eosinophil chemotactic factor in the blister fluid of patients with incontinentia pigmenti. J Dermatol 1985;12:363-8.
130. Takematsu H, Terui T, Torinuki W, Tagami H. Incontinentia pigmenti: eosinophil chemotactic activity of the crusted scales in the vesiculobullous stage. Br J Dermatol 1986;115:61-6.
131. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999; 21:291-5.
132. Jean-Baptiste S, O'Toole EA, Chen M, Guitart J, Paller A, Chan LS. Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clin Exp Immunol 2002;127:470-8.
133. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-56.
134. Ma S, Rao L, Freedberg IM, Blumenberg M. Transcriptional control of K5, K6, K14, and K17 keratin genes by AP-1 and NF-kappaB family members. Gene Expr 1997;6:361-70.
135. Seitz CS, Lin Q, Deng H, Khavari PA. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci U S A 1998;95: 2307-12.
136. Pinheiro M, Freire-Maia N. Ectodermal dysplasias: a clinical classification and a causal review. Am J Med Genet 1994;53: 153-62.
137. Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000;67:1555-62.
138. Doffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001;27:277-85.
139. Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001;2: 223-8.
140. Aradhya S, Courtois G, Rajkovic A, Lewis RA, Levy M, Israel A, et al. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKKgamma). Am J Hum Genet 2001;68:765-71.
141. O'Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 2000;21:206-9.
142. Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JG, Dewulf N, et al. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappaB activation. J Biol Chem 2000;275:18586-93.
143. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
144. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96.
145. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
146. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25:153-9.